Transaction #32353 · Form 4 · 0001193125-26-418101
CRISPR Therapeutics AG · Exercise / conversion · Common Shares
CRISPR Therapeutics AG · Transacted October 6, 2026 · Filed October 8, 2026
What does this filing report?
An SEC Form 4 filing for CRISPR Therapeutics AG records an exercise / conversion involving Common Shares on October 6, 2026. The reported quantity was 1,990. The filing date is October 8, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- CRISPR Therapeutics AG
- Company CIK
- 0001674416
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 1,990
- Reported price
- 13.62
- Reference value
- 27,103.8
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 96,774
- Ownership description
- Not reported
- SEC acceptance time
- Oct 8, 2026, 5:35 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- KASINGER JAMES R. ↗
General Counsel and Secretary
CIK 0001708172
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.
- F2
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3
- This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.